OOIR: Observatory of International Research

Papers

(The H4-Index of European Journal of Clinical Pharmacology is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Association study identifies genetic determinants and non-genetic factors on steady-state plasma and therapeutic outcome of galantamine in mixed dementia	158
Understanding attitudes towards psychiatric medications: a comparative study of patients, healthcare professionals, and general population perspectives	73
Anticholinergic burden and cognitive performance: cross-sectional results from the ELSA-Brasil study	61
Might chronic spontaneous urticaria develop after SARS-CoV-2 vaccinations?	46
Oral Melatonin for Pain Relief During Venepuncture in Neonates– a Pilot Randomized Control Trial	41
How to make the best of NLRP3 inhibitors in patients with COVID-19?	37
A systematic literature review of economic evaluations of setmelanotide	36
Population pharmacokinetics and pharmacodynamics of meropenem in critically ill patients with renal impairment or on continuous renal replacement therapy	35
Signal detection between 5-alpha reductase inhibitors and the risk of suicidality and depression: an international pharmacovigilance analysis	32
Incidence and risk factors of drug-induced kidney injury in children: a systematic review and meta-analysis	32
A Study Of the effect of Sex on drug dosing, concentrations, and pharmacogenomics in the Montreal Heart Institute Hospital Cohort (SOS-PGx): methodology and research progress	30
Identification of novel signal of DRESS associated with antibiotics: a disproportionality analysis of the FDA adverse event reporting system (FAERS) database	29
Correction to: A real-world pharmacovigilance study of adverse events associated with esketamine: disproportionality analysis and detection of potential drug-drug interaction signals	29
A phase 1 study in healthy participants to characterize the safety and pharmacology of inclacumab, a fully human anti-P-selectin antibody, in development for treatment of sickle cell disease	29
Lowering cyclosporine trough concentration threshold effectively mitigates acute graft-versus-host disease in children with severe β-Thalassemia post hematopoietic stem cell transplantation	28
Usefulness of mirtazapine and SSRIs in late-life depression: post hoc analysis of the GUNDAM study	26
Beyond safety: adverse events and unanticipated advantages of SGLT2 inhibitors	25
The efficacy and safety of direct oral anticoagulants versus vitamin K antagonists in patients with left-sided bioprosthetic heart valves and atrial fibrillation: a systematic review and meta-analysis	25
Use of overactive bladder anticholinergic medications associated with falls leading to emergency department visits: results from the ADRED study	25
Effects of sodium-glucose cotransporter 2 inhibitors on renal risk factors in patients with abnormal glucose metabolism: a meta-analysis of randomized controlled trials	25
Comment on “Use of statins and risks of ovarian, uterine, and cervical diseases: a cohort study in the UK Biobank”	22
Challenges of pediatric pharmacotherapy: A narrative review of pharmacokinetics, pharmacodynamics, and pharmacogenetics	21
Clinical pharmacology—how it shapes the drug development journey	21
Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation	21
Assessment of body mass-related covariates for rifampicin pharmacokinetics in healthy Caucasian volunteers	21

Association of high risk of liver fibrosis in patients with serious outcomes of adverse drug reactions